The University of Oslo is Norway’s largest university with about 5 900 employees and 27 700 students. We offer interesting career opportunities and a good work environment. The university aims to achieve a balanced gender composition in the workforce and to recruit people with ethnic minority backgrounds.
Centre for Molecular Medicine Norway (NCMM, http://www.ncmm.uio.no) was established in 2007 as a partner institution of the European Molecular Biology Laboratory (http://www.embl.org) together with Nordic nodes formolecular medicine in Finland (FIMM) and Sweden (MIMS). NCMM is a joint venture of the University of Oslo, Health Region South-East and the Research Council of Norway. NCMM is located in brand new laboratories in the University of Oslo and Oslo University Hospital Biomedical Campus in the Oslo Research Park and Preclinical Medicine buildings.
Centre for Molecular Medicine Norway (NCMM)-Nordic EMBL Partnership
Postdoctoral Fellowship – Gene regulation, drug resistance and systems biology of breast cancer
The Centre for Molecular Medicine Norway (NCMM), http://www.ncmm.uio.no was established in 2008 as anational partnership institution with the European Molecular Biology Laboratory (http://www.embl.org) together with similar centre in Sweden and Finland under the Nordic EMBL Partnership with an overall objective of facilitating translation of discoveries in basic medical research into clinical practice. NCMM focuses particularly on disease mechanisms where Norway has clear strengths and will investigate mechanisms of non-communicable diseases such as cancer, cardiovascular and CNS-related diseases, inflammation and immune disorders and stem cells.
The new established Breast Cancer Research group of Antoni Hurtado (NCMM) and the group of Anne-Lise Børresen/Kristine Kleivi Sahlberg (Department of Genetics, Institute for Cancer Research, Oslo University Hospital – The Norwegian Radium Hospital, Oslo) are seeking to recruit a postdoctoral research fellow for a two-year period. Both laboratories study the mechanism of resistance to breast cancer treatments. The offered project aims to investigate the deregulated signaling pathways in HER2+ cancers in relation to treatment response and investigate the molecular interactions of ER and HER2 pathways. Using in silico studies and in combination with state of the art technologies in prospective cell and clinical samples this project plan to achieve the following objectives: 1) Integrated genomic analysis to study the signaling pathways in HER2+ cancers in relation to drug response and 2) Study of the molecular interaction between ER and HER-2 pathways.
We seek a highly motivated candidate holding a PhD who appreciates working in an international and interactive environment. The ideal applicant will hold experience in bioinformatic analysis of genomic data and a versatile range of laboratory skills allowing him/her to progress from gene-level descriptions to functional understanding. The candidate is expected to work together with other PhDs/Postdocs/scientists and clinicians in a team. Good communication and collaboration skills are required.
The University of Oslo has an agreement for all employees, aiming to secure rights to research results and intellectual property.
Applications should include a covering letter summarizing the applicant’s career, past research accomplishments (1-2 pages), CV and a list of publications, copies of certificates and grades, and names of three references.
The position will be placed as SKO (Position Code)1352 Post-doctor, with salary range depending on qualifications: pay grade 57 – 62 (NOK 456 100 – NOK 499 500). The position is for two years with preferred start within October 2011.
For further information, see http://www.ncmm.uio.no and http://www.ous-research.no/genetics/. Inquiries regarding the post can be directed to Antoni Hurtado (email@example.com), Anne-Lise Børresen-Dale (firstname.lastname@example.org) or Kristine Kleivi Sahlberg (email@example.com). Applications should be sent electronically as a single PFD-file to the Centre for Molecular Medicine Norway (NCMM) at firstname.lastname@example.org no later than August 15th, 2011 labeled with Ref.no.2011/9231 – NCMM Postdoctoral Fellowship in the subject field.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature. 2008
Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011
CAO Elin Kaurstad
Telephone: +47 22840608
Mobile: +47 91611585
Besøksadresse Problemveien 7 0313 OSLO
Postadresse Postboks 1072 Blindern 0316 OSLO
Telefon 22 85 50 50 Faks 22 85 62 50